Pyxis Oncology (PYXS) Stock Forecast, Price Target & Predictions
PYXS Stock Forecast
Pyxis Oncology stock forecast is as follows: an average price target of $8.50 (represents a 402.96% upside from PYXS’s last price of $1.69) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
PYXS Price Target
The average price target for Pyxis Oncology (PYXS) is $8.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $7.00. This represents a potential 402.96% upside from PYXS's last price of $1.69.
PYXS Analyst Ratings
According to 3 Wall Street analysts, Pyxis Oncology's rating consensus is 'Buy'. The analyst rating breakdown for PYXS stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Pyxis Oncology Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 16, 2024 | Swayampakula Ramakanth | H.C. Wainwright | $7.00 | $3.52 | 98.86% | 314.20% |
| Aug 07, 2024 | Bradley Canino | Stifel Nicolaus | $10.00 | $3.13 | 219.49% | 491.72% |
| May 07, 2024 | Farzin Haque | Jefferies | $10.00 | $4.31 | 132.02% | 491.72% |
The latest Pyxis Oncology stock forecast, released on Aug 16, 2024 by Swayampakula Ramakanth from H.C. Wainwright, set a price target of $7.00, which represents a 98.86% increase from the stock price at the time of the forecast ($3.52), and a 314.20% increase from PYXS last price ($1.69).
Pyxis Oncology Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $9.00 |
| Last Closing Price | $1.69 | $1.69 | $1.69 |
| Upside/Downside | -100.00% | -100.00% | 432.54% |
In the current month, the average price target of Pyxis Oncology stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Pyxis Oncology's last price of $1.69. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 05, 2023 | RBC Capital | Outperform | Initialise | |
| Apr 25, 2022 | Zacks Investment Research | Hold | Upgrade |
Pyxis Oncology's last stock rating was published by H.C. Wainwright on Aug 16, 2024. The company gave PYXS a "Buy" rating, the same as its previous rate.
Pyxis Oncology Financial Forecast
Pyxis Oncology Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $9.33M | $2.83M | - | - | - | - | - | - | $125.00K | $125.00K | $125.00K | $125.00K | $100.00K | $100.00K | $100.00K | $4.13M | $200.00K | $833.00K | $625.00K |
| High Forecast | $9.33M | $2.83M | - | - | - | - | - | - | $125.00K | $125.00K | $125.00K | $125.00K | $100.00K | $100.00K | $100.00K | $4.13M | $200.00K | $833.00K | $625.00K |
| Low Forecast | $9.33M | $2.83M | - | - | - | - | - | - | $125.00K | $125.00K | $125.00K | $125.00K | $100.00K | $100.00K | $100.00K | $4.13M | $200.00K | $833.00K | $625.00K |
| # Analysts | 1 | 1 | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Pyxis Oncology's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PYXS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Pyxis Oncology EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-17.77M | $-25.35M | $-18.12M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict PYXS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Pyxis Oncology's previous annual EBITDA (undefined) of $NaN.
Pyxis Oncology Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-15.60M | $-23.05M | $-15.90M |
| Avg Forecast | $-18.94M | $-20.36M | $-20.00M | $-20.14M | $-19.82M | $-19.96M | $-20.10M | $-20.24M | $-19.02M | $-18.62M | $-18.82M | $-20.04M | $-19.69M | $-19.33M | $-20.54M | $-14.49M | $-28.83M | $-30.78M | $-39.27M |
| High Forecast | $-18.94M | $-20.36M | $-20.00M | $-20.14M | $-19.82M | $-19.96M | $-20.10M | $-20.24M | $-19.02M | $-18.62M | $-18.82M | $-17.61M | $-17.23M | $-19.33M | $-20.54M | $-14.49M | $-20.59M | $-30.78M | $-39.27M |
| Low Forecast | $-18.94M | $-20.36M | $-20.00M | $-20.14M | $-19.82M | $-19.96M | $-20.10M | $-20.24M | $-19.02M | $-18.62M | $-18.82M | $-23.07M | $-23.38M | $-19.33M | $-20.54M | $-14.49M | $-33.54M | $-30.78M | $-39.27M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.54% | 0.75% | 0.40% |
Pyxis Oncology's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PYXS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Pyxis Oncology SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $6.16M | $10.67M | $6.73M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Pyxis Oncology's average Quarter SG&A projection for Mar 24 is -, based on 1 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to PYXS last annual SG&A of $6.16M (Dec 23).
Pyxis Oncology EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.27 | $-0.00 | $-0.41 |
| Avg Forecast | $-0.31 | $-0.34 | $-0.33 | $-0.33 | $-0.33 | $-0.33 | $-0.33 | $-0.33 | $-0.31 | $-0.31 | $-0.31 | $-0.33 | $-0.32 | $-0.32 | $-0.34 | $-0.24 | $-0.47 | $-0.51 | $-0.65 |
| High Forecast | $-0.31 | $-0.34 | $-0.33 | $-0.33 | $-0.33 | $-0.33 | $-0.33 | $-0.33 | $-0.31 | $-0.31 | $-0.31 | $-0.29 | $-0.28 | $-0.32 | $-0.34 | $-0.24 | $-0.34 | $-0.51 | $-0.65 |
| Low Forecast | $-0.31 | $-0.34 | $-0.33 | $-0.33 | $-0.33 | $-0.33 | $-0.33 | $-0.33 | $-0.31 | $-0.31 | $-0.31 | $-0.38 | $-0.39 | $-0.32 | $-0.34 | $-0.24 | $-0.55 | $-0.51 | $-0.65 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.57% | 0.00% | 0.63% |
According to undefined Wall Street analysts, Pyxis Oncology's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PYXS previous annual EPS of $NaN (undefined).
Pyxis Oncology Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ELEV | Elevation Oncology | $0.67 | $9.00 | 1243.28% | Buy |
| INZY | Inozyme Pharma | $2.94 | $16.00 | 444.22% | Buy |
| PYXS | Pyxis Oncology | $1.63 | $8.50 | 421.47% | Buy |
| XFOR | X4 Pharmaceuticals | $0.74 | $3.67 | 395.95% | Buy |
| PDSB | PDS Bio | $1.96 | $9.00 | 359.18% | Buy |
| ZURA | Zura Bio | $2.51 | $10.00 | 298.41% | Buy |
| TERN | Terns Pharmaceuticals | $6.80 | $18.67 | 174.56% | Buy |
| MREO | Mereo BioPharma Group | $3.40 | $8.00 | 135.29% | Buy |
| CRVS | Corvus Pharmaceuticals | $7.39 | $12.50 | 69.15% | Buy |
| HOOK | HOOKIPA Pharma | $2.13 | $3.00 | 40.85% | Buy |